|Bid||14.91 x 3100|
|Ask||14.93 x 800|
|Day's Range||14.45 - 14.98|
|52 Week Range||5.61 - 25.10|
|Beta (3Y Monthly)||4.03|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The Wisconsin Retirement System, one of only two fully funded state pensions, also slashed its holdings in PG&E, the struggling California utility, last quarter.
Wall Street has handed out not one, two, or three... but seven price-target cuts to this marijuana stock since the month began.
Cronos Group Inc (NASDAQ:CRON) through its subsidiary Peace Naturals Project, has signed a multi-year supply agreement with Medipharm, an affiliate of Medipharm Labs Corp (OTCMKTS:MEDIF) on May 13, 2019. Under the terms of the agreement, Medipharm Labs will supply Peace Naturals $30 million worth of high-grade private label cannabis concentrate for over 18 months. The […]The post Cronos Inks $30 Million Supply Agreement with Medipharm appeared first on Market Exclusive.
Investing.com - Cannabis company Cronos Group climbed in midday trading following a multi-year deal with MediPharm Labs on cannabis and cannabis concentrate supply.
MediPharm Labs Corp. (LABS.V) (MEDIF) (“MediPharm Labs”) a leader in specialized, research-driven cannabis extraction and cannabinoid isolation, is pleased to announce that it has entered into a multi-year supply agreement with Cronos Group Inc. (CRON) (CRON) (“Cronos Group”). MediPharm Labs will supply Cronos Group with approximately $30 million of high-quality private label cannabis concentrate over 18-months, and, subject to certain renewal and purchase options, potentially up to $60 million over 24-months. In addition, Cronos Group has selected MediPharm Labs’ state of the art extraction facility in Barrie, Ontario, as a preferred partner to fulfill certain of its processing needs, under a separate tolling arrangement.
Cronos Group Inc. (CRON.TO) (CRON.TO) (“Cronos Group” or the “Company”), is pleased to announce that it has entered into a multi-year supply agreement with MediPharm Labs Corp. (LABS.V) (MEDIF) (“MediPharm Labs”). MediPharm Labs will supply Cronos Group with approximately $30 million of high-quality private label cannabis concentrate over 18-months, and, subject to certain renewal and purchase options, potentially up to $60 million over 24-months.
The Market Is Sinking and Taking the Cannabis Sector Along(Continued from Prior Part)Cronos declinesCronos Group (CRON) underwent a deep selloff after it reported its earnings last week, and it lost another 7% during the day. See Cronos Group:
Cannabis Sector Fell on CRON's Earnings and Trade TensionsCannabis sector last week Last week was lackluster for the cannabis sector, and most of the stocks in the sector ended in the negative territory.
Aurora is taking the road less traveled in finding a partner outside of the cannabis industry. But could the road be dead-end?
Canadian cannabis vendor (CRON) has $2 billion in its pocket and yet says it can’t find enough good marijuana. The company blamed a shortage of suitable product on Canada’s wholesale market for its paltry $4 million in marijuana sales in the most recent quarter.
Cannabis Stocks Mixed a Day after Cronos Group’s Earnings(Continued from Prior Part)Mixed bagThe overall cannabis sector was a mixed bag today with some of the big stocks trading in negative territory. The Horizons Marijuana Life Sciences ETF
Cannabis Stocks Mixed a Day after Cronos Group’s EarningsCronos earningsCronos Group (CRON) reported its earnings yesterday, and the stock sank about 8% after the release. Analysts also rushed to revise their ratings and price targets for the
Cronos Group: Analysts' Ratings after Its Q1 Earnings(Continued from Prior Part)ValuationsCronos Group (CRON) stock has taken a hit of ~8% after its first-quarter earnings. As a result, the valuation multiples will likely be impacted. Cronos
Cronos Group: Analysts' Ratings after Its Q1 EarningsCronos GroupCronos Group (CRON) reported its first-quarter earnings on May 9. The company’s net revenues were 6.9 million Canadian dollars—a rise of ~133% YoY (year-over-year) from 2.9 million
Here's what you should know about this fast-growing cannabis company following its latest quarterly financial results.
Cronos Group Sinks after Reporting Its Q1 Earnings Results(Continued from Prior Part)Kilograms soldCronos Group (CRON) reported 120% year-over-year sales growth in the first quarter, reflecting increased cannabis sales, but if we compare its results